<DOC>
	<DOCNO>NCT02960646</DOCNO>
	<brief_summary>The goal clinical research study learn give modified stem cell transplant less likely cause graft-versus-host disease ( GVHD ) patient certain type blood disorder blood cancer make patient less likely develop GVHD . Participants also receive melphalan fludarabine part regular chemotherapy total body irradiation ( TBI ) regimen . Before participant receives stem cell transplant , `` modify '' remove certain type T cell cause GVHD . GVHD occur transplant immune tissue , T cell stem cell , attack tissue recipient 's body .</brief_summary>
	<brief_title>Clinical Trial Using Engineered Peripheral Blood Graft Haploidentical Transplantation</brief_title>
	<detailed_description>Central Venous Catheter : The chemotherapy drug study give vein participant ' central venous catheter ( CVC ) . A CVC sterile flexible tube needle place large vein participant local anesthesia . Blood sample also draw participant 's CVC . The CVC remain participant 's body treatment . Participant 's doctor explain procedure detail , require sign separate consent form . Chemotherapy Stem Cell Infusion : Participant receive 1 2 chemotherapy treatment ( high-dose regimen reduced-intensity regimen ) choose doctor . The treatment select base participant 's age health . The high-dose regimen include high dose melphalan reduced-intensity regimen . The dos fludarabine cyclophosphamide . Study Drug Administration : On Day -7 ( 7 day receive modified stem cell transplant ) , participant admit hospital give fluid vein . On Day -6 , participant receive melphalan vein 30 minute fludarabine vein 1 hour . Fludarabine melphalan give treat cancer lower immune system order low risk reject donor cell . On Days -5 -3 , participant receive fludarabine vein 1 hour . On Day -2 , participant receive total body irradiation ( TBI ) . TBI involve delivery high dos radiation design destroy cancer cell and/or low immune system order low risk body reject new stem cell . On Day -1 , participant `` rest '' ( receive chemotherapy ) . On Day 0 , participant receive modify stem cell transplant vein . The infusion last anywhere 30 minute several hour . On Days +3 +4 , participant receive cyclophosphamide vein 3 hour . Cyclophosphamide give low immune system order low risk GVHD . Participant also receive mesna vein 30 minute every 4 hour total 10 mesna dos Days +3 +4 . Mesna give low risk side effect bladder cause cyclophosphamide . Starting Day +5 , participant one first 6 patient enrol study , receive tacrolimus help low risk GVHD . Tacrolimus give vein continuous infusion 2 week . After 2 week take tacrolimus vein , participant take tacrolimus mouth pill least 4 month . Starting Day +7 , participant receive filgrastim injection skin 1 time day , blood cell level high enough . Filgrastim design help growth type healthy white blood cell fight infection . Depending type disease , participant 's doctor may decide give rituximab vein several hour Days -13 , -6 , 1 , 8 . Rituximab give help body get rid abnormal white blood cell . Participant give standard drug help decrease risk side effect . Participant may ask study staff information drug give risk . Study Testing : Before participant send home hospital and/or clinic , receive additional write instruction . These instruction include often participant come hospital/clinic , standard drug take home , side effect may . After finish chemotherapy cell infusion , participant 's follow-up care routine standard care follow-up patient receive allogeneic stem cell transplantation receive . At visit , participant physical exam check symptom GVHD . Participant ask side effect may . Blood ( 1 tablespoon ) drawn routine test . Mouse protein antibody use T cell removal process . If participant 's body become immune protein , may develop antibody mouse antibody ( call `` human anti-mouse antibody '' HAMA ) . Blood sample draw modified stem cell transplant 3 month modify stem cell transplant use compare sample participant 's blood collect transplant complete , make sure develop immune system reaction mouse protein antibody . If participant leaf study 3 month stem cell transplant , blood drawn check HAMA , possible . If doctor think need , participant bone marrow aspiration check status disease . To collect bone marrow aspirate , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Blood ( 4 tablespoon ) draw test genetic makeup function modify stem cell check status disease 1 , 2 , 3 , 6 , 9 , 12 month modify stem cell transplant . Length Treatment : Participant study 2 year . Participant may take study early doctor think best interest , disease get bad come back needs treatment , intolerable side effect occur , unable follow study direction , choose leave study early . If reason participant want leave study early , must talk study doctor . It may life-threatening leave study participant start receive study drug receive stem cell transplant blood cell count dangerously low . This investigational study . The study drug FDA approve commercially available treatment blood cancer and/or stem cell transplant . The way researcher remove T cell infusion modify stem cell transplant investigational FDA approve . Up 12 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Lack HLA match related donor , lack immediately available 8/8 HLA match unrelated donor . 2 . Patients must &gt; /= 18 &lt; /= 60 , diagnose highrisk and/or advance hematologic malignancy define one following : 3 . Acute lymphocytic leukemia ( ALL ) CR1 highrisk feature include adverse cytogenetic ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL gene rearrangement ; second great morphologic remission ; persistent minimal residual disease ; 4 . Acute myeloid leukemia ( AML ) CR1 intermediaterisk disease persistent detectable MRD , highrisk feature define : great 1 cycle induction therapy require achieve remission ; precede myelodysplastic syndrome ( MDS ) myeloproliferative disease ; presence FLT3 mutation internal tandem duplication , DNMT3a , TET2 , MLLPTD , ASXL1 , PHF6 ; FAB M6 M7 classification ; adverse cytogenetics include : 5 , del 5q , 7 , del7q , abnormality involve 3q , 9q , 11q , 20q , 21q , 17 , +8 , complex [ &gt; 3 abnormality ] ; 5 . Patients AML must less 10 % bone marrow blast &lt; 100/mcL absolute peripheral blood blast count ; 6 . MDS IPSS intermediate2 high , therapyrelated MDS CMML ; 7 . Aplastic anemia ANC &lt; 1,000 transfusion dependent fail immunosuppression therapy ; 8 . Chronic myeloid leukemia ( CML ) &gt; /=1st chronic phase , fail &gt; /=2 line tyrosine kinase inhibitor ; patient progress blast phase must morphologic remission transplant ; 9 . Relapsed Hodgkin 's disease nonHodgkin 's lymphoma ( NHL ) ; 10 . Patients chemosensitive chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL ) persistent recurrent disease fludarabinebased regimen &lt; 25 % involvement CLL/SLL cell ; 11 . Zubrod performance status 01 Karnofsky performance status &gt; 70 % . Patients &gt; 50 year Sorror Comorbidity Index &lt; /= 3 ; 12 . Available haploidentical donor willing eligible undergo peripheral blood collection ; 13 . LVEF &gt; 40 % ; 14 . Bilirubin &lt; /= 1.5 mg/dl ( unless Gilbert 's syndrome ) , ALT AST &lt; /= 200 IU/ml adult . Conjugated ( direct ) bilirubin &lt; 2x upper limit normal ; 15 . Serum creatinine clearance &gt; /= 50 ml/min ( calculate CockcroftGault formula ) ; 16 . Diffusing capacity carbon monoxide ( DLCO ) &gt; /= 45 % predict correct hemoglobin . 17 . Patient patient 's legal representative must provide write informed consent . 1 . HIV positive ; active hepatitis B C. 2 . Patients active infection . The PI final arbiter eligibility . 3 . Liver cirrhosis great grade 1 stage 1 inflammation/fibrosis . 4 . Uncontrolled CNS involvement tumor cell within past 2 month . 5 . History another primary malignancy remission least 3 year . ( The follow exempt 3year limit : nonmelanoma skin cancer , fully excise melanoma situ [ Stage 0 ] , curatively treat localized prostate cancer , cervical carcinoma situ biopsy squamous intraepithelial lesion PAP smear . ) 6 . Positive Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 7 . Inability comply medical therapy followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Acute lymphocytic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Hodgkin 's disease</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Small lymphocytic lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>Myelodysplastic syndrome ( MDS</keyword>
	<keyword>MDS</keyword>
	<keyword>Aplastic anemia</keyword>
	<keyword>Modified ( CD45RA deplete ) peripheral blood ( PB ) stem cell infusion</keyword>
	<keyword>T cell</keyword>
	<keyword>Haploidentical transplantation</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>